View Archive »
About The Cover
The cover for the December issue of Oncotarget was taken from Mira et al. Entitled " Lovastatin regulates Tg-neu tumor vascular phenotype.", shown is FITC-lectin-perfused Vhcl-.
|
|
Table of Contents
Editorial Materials
|
| MicroRNAs as regulators of tumorassociated stromal cells |
|
https://doi.org/10.18632/oncotarget.1625
|
| 2166-2167 |
|
| Wip1 and ATM in tumor evolution: role for BRCA1 |
|
https://doi.org/10.18632/oncotarget.1661
|
| 2170 |
Reviews
|
| Chemokines in tumor progression and metastasis |
|
https://doi.org/10.18632/oncotarget.1426
|
| 2171-2185 |
|
| Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms |
|
https://doi.org/10.18632/oncotarget.1497
|
| 2186-2207 |
Brief Reports
|
| A lossoffunction mutation in PTCH1 suggests a role for autocrine hedgehog signaling in colorectal tumorigenesis |
|
https://doi.org/10.18632/oncotarget.1651
|
| 2208-2211 |
Research Papers
|
| Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumorinitiating cell phenotype |
|
https://doi.org/10.18632/oncotarget.1143
|
| 2212-2224 |
|
| Combinatorial antitumor effect of HDAC and the PI3KAktmTOR pathway inhibition in a Pten defecient model of prostate cancer |
|
https://doi.org/10.18632/oncotarget.1314
|
| 2225-2236 |
|
| Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma |
|
https://doi.org/10.18632/oncotarget.1357
|
| 2237-2248 |
|
| Induction of apoptosis by directing oncogenic BcrAbl into the nucleus |
|
https://doi.org/10.18632/oncotarget.1339
|
| 2249-2260 |
|
| Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma |
|
https://doi.org/10.18632/oncotarget.1302
|
| 2261-2270 |
|
| A tumorpromoting mechanism mediated by retrotransposonencoded reverse transcriptase is active in human transformed cell lines |
|
https://doi.org/10.18632/oncotarget.1403
|
| 2271-2287 |
|
| A lovastatinelicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors |
|
https://doi.org/10.18632/oncotarget.1376
|
| 2288-2301 |
|
| Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5 |
|
https://doi.org/10.18632/oncotarget.1490
|
| 2302-2316 |
|
| HOXA11 hypermethylation is associated with progression of nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.1464
|
| 2317-2325 |
|
| Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity |
|
https://doi.org/10.18632/oncotarget.1554
|
| 2326-2338 |
|
| SCFβTRCP targets MTSS1 for ubiquitinationmediated destruction to regulate cancer cell proliferation and migration |
|
https://doi.org/10.18632/oncotarget.1446
|
| 2339-2353 |
|
| Inhibition of SIRT2 in merlin/NF2mutant Schwann cells triggers necrosis |
|
https://doi.org/10.18632/oncotarget.1422
|
| 2354-2365 |
|
| Ovarian cancer stemlike cells with induced translineagedifferentiation capacity and are suppressed by alkaline phosphatase inhibitor |
|
https://doi.org/10.18632/oncotarget.1424
|
| 2366-2382 |
|
| EI24 regulates epithelialtomesenchymal transition and tumor progression by suppressing TRAF2mediated NFκB activity |
|
https://doi.org/10.18632/oncotarget.1434
|
| 2383-2396 |
|
| 1 alpha 25dihydroxylvitamin D3 promotes Bacillus CalmetteGuérin immunotherapy of bladder cancer |
|
https://doi.org/10.18632/oncotarget.1494
|
| 2397-2406 |
|
| In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics |
|
https://doi.org/10.18632/oncotarget.1527
|
| 2407-2418 |
|
| Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer |
|
https://doi.org/10.18632/oncotarget.1572
|
| 2419-2429 |
|
| Gefitinib resistance resulted from STAT3mediated Akt activation in lung cancer cells |
|
https://doi.org/10.18632/oncotarget.1431
|
| 2430-2438 |
|
| Evaluation of Zinc II chelators for inhibiting p53mediated apoptosis |
|
https://doi.org/10.18632/oncotarget.1535
|
| 2439-2450 |
|
| Dietary protein restriction inhibits tumor growth in human xenograft models |
|
https://doi.org/10.18632/oncotarget.1586
|
| 2451-2461 |
|
| High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer |
|
https://doi.org/10.18632/oncotarget.1578
|
| 2462-2475 |
|
| FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene FBXW7 |
|
https://doi.org/10.18632/oncotarget.1581
|
| 2476-2486 |
|
| Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growthinhibitory to growthpromoting effects |
|
https://doi.org/10.18632/oncotarget.1604
|
| 2487-2501 |
|
| Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth |
|
https://doi.org/10.18632/oncotarget.1540
|
| 2502-2511 |
|
| Loss of Ecadherin activates EGFRMEK/ERK signaling which promotes invasion via the ZEB1/MMP2 axis in nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.1463
|
| 2512-2522 |
|
| Extracellular p53 fragment reenters KRas mutated cells through the caveolin1 dependent early endosomal system |
|
https://doi.org/10.18632/oncotarget.1550
|
| 2523-2531 |
|
| The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer |
|
https://doi.org/10.18632/oncotarget.1503
|
| 2532-2549 |
|
| Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPKmediated energetic reprogramming |
|
https://doi.org/10.18632/oncotarget.1508
|
| 2550-2566 |
Research Perspectives
|
| Endothelial hypoxic metabolism in carcinogenesis and dissemination : HIFA isoforms are a NO metastatic phenomenon |
|
https://doi.org/10.18632/oncotarget.1461
|
| 2567-2576 |
|
| Antioxidative stress response genes: bioinformatic analysis of their expression and relevance in multiple cancers |
|
https://doi.org/10.18632/oncotarget.1658
|
| 2577-2590 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
